The FDA has approved Abilify Asimtufii (aripiprazole), administered every 2 months, for schizophrenia and bipolar I disorder.

The active ingredient in Abilify Maintena is aripiprazole, which is a second-generation antipsychotic that is used to treat psychiatric conditions, including bipolar I. Second-generation ...

Find out about the dosages of Abilify for treating certain mental health conditions or mood disorders in adults and some children. Also, get the facts on Abilify's forms, strengths, and dosing ...

Learn about uses, dosage, and more of Abilify Asimtufii (aripiprazole), which is a prescription injection that treats schizophrenia and bipolar I disorder in adults.

Aripiprazole oral tablet is used for schizophrenia, bipolar disorder, autism, and Tourette’s syndrome. Learn about side effects and more.

Abilify Asimtufii, the bipolar I disorder treatment from Otsuka and Lundbeck, has entered the world of CGI animation as part of a multichannel direct-to-consumer (DTC) campaign. The two drugmakers ...

NEW YORK, April 6 (Reuters) - Bristol-Myers Squibb Co said on Monday it will sell its Abilify schizophrenia drug more than two years longer than expected, helping to shore up profits after the ...

Bristol-Myers Squibb Co. will pay $19.5 million to settle allegations that the London-based drugmaker improperly marketed and promoted its anti-psychotic drug Abilify, reports Reuters.

The settlement agreement, reached on Feb. 15 and disclosed on Tuesday in an order by the federal judge overseeing the Abilify multidistrict litigation, is confidential and no further details on ...